Advanced Solid Tumor
Conditions
Brief summary
This is a open-label, 3+3 design, dose escalation and expansion, phase I study, to evaluate the safety and tolerability, and to determine the Recommended Phase II Dose (RP2D) of TR128 when administered qd in patients with advanced solid tumors. Up to 5 cohorts of 3-6 patients each will be treated in dose escalation phase of the study. One cycle is 28 days. Dose expansion phase to further evaluate the safety, tolerability and preliminary anti-tumor activity of TR128 at the RP2D.
Detailed description
This phase I study of TR128 will investigate the tolerability, safety, pharmacokinetics (PK) and preliminary efficacy of TR128, and will define the maximum tolerated dose (MTD) of TR128 using 3+3 design. A dose expansion phase will identify the recommended phase 2 dose. In this clinical study, TR128 is given orally daily. A treatment cycle is defined as 28 days. Patients will receive study treatment until criteria for study termination are met. A safety follow-up visit will be conducted 28 days after the last dose of study treatment. Patients who discontinue study treatment for reasons other disease progression will have post-treatment follow-up for disease assessment until start of new anticancer treatment, patient withdraws consent, is lost to follow-up, death, or until the sponsor stops the study, whichever comes first. Adverse events (AEs) will be assessed using the NCI Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0. Tumor response will be assessed by computed tomography (CT) and /or magnetic resonance imaging (MRI) scan using RECIST1.1 criteria, assessed by the investigator.
Interventions
DRUGTR128
TR128 will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons. Starting dose is 100mg, with escalation to 500mg.
Sponsors
Tarapeutics Science Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Dose escalation and expansion
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* fully understand the procedures of the clinical study and participate voluntarily with signed and dated written informed consent form, comply with the requirements of the study protocol. * males and/or females at least 18 years old when signing the informed consent form. * histologically or cytologically confirmed patients with advanced malignant solid tumors, eligible patients must have failed standard treatment, no standard treatment, or not suitable for standard treatment at this stage as determined by the investigator. * measurable disease with at least one lesion amenable to response assessment per RECIST 1.1. * eastern cooperative oncology group performance status (ECOG) ≤1 at screening. * life expectancy of at least 3 months. * acceptable organ function: Absolute neutrophil count(ANC)≥1.5×109/L; Platelet count(PLT)≥90×109/L; Hemoglobin(Hb)≥90 g/L; International Normalized Ratio (INR) or Prothrombin Time (PT)≤1.5×Upper limit of normal value (ULN), Activated Partial Thromboplastin Time (APTT)≤1.5×ULN ; Total bilirubin(TBIL)≤1.5×Upper limit of normal value(ULN) (≤3× ULN if there is liver involvement); Alanine aminotransferase(ALT)≤2.5×ULN and aspartate aminotransferase(AST)≤2.5×ULN (≤ 5 × ULN if there is liver involvement); Creatinine (Cr) ≤1.5×ULN or Creatinine Clearance (CCr) ≥50 ml/min (calculated by Cockcroft-Gault formula). * fertile male and female must agree to use medically approved contraceptives during the study and within 6 months after the last dose of the study.
Exclusion criteria
* medical history and surgical history excluded according to the protocol. * any previous medical treatment history exclude from the protocol. * abnormal laboratory results exclude from the protocol. * pregnant and lactating women (currently breast-feeding or less than six months after delivery although not breast-feeding). * unsuitable for the study by the investigator's judgment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum tolerated dose | Throughout the study for approximately 2 years | Evaluated by safety review committee |
| Adverse Events and Serious Adverse Events | from the first dose to within 30 days after the last dose | Frequency, duration, and severity of Adverse Events and Serious Adverse Events evaluated by NCI CTCAE v5.0 |
| Dose limited toxicities | within 28 days after the first dose | Incidence of dose limited toxicities |
| Recommended phase II dose | Throughout the study for approximately 2 years | Evaluated by safety review committee |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| DOR | throughout the study for approximately 2 years | Efficacy-duration of response |
| AUClast | within 31 days after the first dose | Characterize the pharmacokinetic profile of TR128 |
| AUCinf | within 31 days after the first dose | Characterize the pharmacokinetic profile of TR128 |
| DCR | throughout the study for approximately 2 years | Efficacy-disease control rate |
| Tmax | within 31 days after the first dose | Characterize the pharmacokinetic profile of TR128 |
| CL/F | within 31 days after the first dose | Characterize the pharmacokinetic profile of TR128 |
| Vz/F | within 31 days after the first dose | characterize the pharmacokinetic profile of TR128 |
| Cmax | within 31 days after the first dose | Characterize the pharmacokinetic profile of TR128 |
| Terminal half-life (T1/2) | within 31 days after the first dose | Characterize the pharmacokinetic profile of TR128 |
| ORR | throughout the study for approximately 2 years | Efficacy-overall response rate |
| PFS | throughout the study for approximately 2 years | Efficacy-progression free survival |
Countries
China
Contacts
Primary ContactYang Shu, MD. BS.
Outcome results
None listed